LUMO: Lumos Pharma, Inc.
About
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Current Value
$4.331 Year Return
Current Value
$4.331 Year Return
Key Details
Market Cap
$37.45M
P/E Ratio
-1.01
1Y Stock Return
41.97%
1Y Revenue Growth
26.94%
Dividend Yield
0.00%
Price to Book
7.6
Strategies that include LUMO
Stock's related to LUMO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GNW | 24.99% | $3.17B | +28.32% | 0.00% |
| JHX | 24.03% | $15.44B | +11.44% | 0.00% |
| IGT | 23.71% | $3.83B | -28.66% | 4.24% |
| EOLS | 22.96% | $784.55M | +31.53% | 0.00% |
| PRA | 22.13% | $830.78M | +27.17% | 0.00% |
| WOW | 21.80% | $434.90M | +18.48% | 0.00% |
| COUR | 21.54% | $1.08B | -64.26% | 0.00% |
| HCI | 21.24% | $1.16B | +29.00% | 1.48% |
| ETD | 21.08% | $740.01M | +7.77% | 5.25% |
| CABO | 20.93% | $2.24B | -27.54% | 2.99% |
| BKE | 20.81% | $2.40B | +31.47% | 2.96% |
| INTA | 20.77% | $4.48B | +52.18% | 0.00% |
| TTD | 20.43% | $58.94B | +81.35% | 0.00% |
| EVRI | 20.24% | $1.15B | +23.27% | 0.00% |
| USAC | 20.17% | $2.76B | -3.87% | 8.93% |
| EIG | 20.05% | $1.30B | +38.83% | 2.25% |
| ACI | 19.85% | $11.16B | -9.32% | 2.50% |
| DEO | 19.84% | $66.22B | -15.77% | 3.46% |
| MMM | 19.72% | $69.81B | +63.13% | 2.82% |
| AUPH | 19.54% | $1.16B | -6.98% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PSFE | -0.01% | $1.06B | +42.18% | 0.00% |
| BAK | 0.01% | $878.18M | -36.93% | 0.00% |
| NPO | 0.01% | $3.64B | +36.09% | 0.69% |
| ECL | 0.01% | $69.18B | +30.92% | 0.93% |
| CRSR | -0.02% | $689.97M | -47.32% | 0.00% |
| AZPN | -0.02% | $15.62B | +34.34% | 0.00% |
| CEG | 0.03% | $73.37B | +91.48% | 0.59% |
| DOV | 0.04% | $27.26B | +43.51% | 1.03% |
| BPMC | -0.04% | $6.01B | +42.68% | 0.00% |
| NTRA | -0.04% | $21.40B | +200.46% | 0.00% |
| LXFR | -0.04% | $387.04M | +72.02% | 3.60% |
| ICHR | -0.04% | $1.03B | +18.32% | 0.00% |
| AFYA | 0.06% | $1.47B | -16.48% | 0.00% |
| IQ | -0.06% | $1.10B | -56.00% | 0.00% |
| SHG | 0.06% | $19.42B | +36.63% | 2.96% |
| CPRX | -0.07% | $2.55B | +55.68% | 0.00% |
| SPSC | -0.07% | $6.67B | +3.18% | 0.00% |
| CLFD | -0.07% | $398.66M | +4.48% | 0.00% |
| KBR | -0.08% | $7.77B | +11.73% | 1.00% |
| API | -0.08% | $299.01M | +33.12% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QURE | -19.60% | $283.68M | -13.52% | 0.00% |
| DXCM | -14.56% | $29.25B | -31.28% | 0.00% |
| GRVY | -12.25% | $466.13M | -4.24% | 0.00% |
| SMC | -11.59% | $383.35M | +97.26% | 0.00% |
| POAI | -10.56% | $4.29M | -78.60% | 0.00% |
| WTW | -10.34% | $30.98B | +26.60% | 1.13% |
| FRHC | -10.33% | $7.09B | +39.10% | 0.00% |
| RGEN | -10.24% | $7.20B | -18.16% | 0.00% |
| GLW | -10.23% | $40.49B | +68.23% | 2.37% |
| RLMD | -10.20% | $89.92M | +1.36% | 0.00% |
| MMYT | -10.10% | $11.31B | +142.64% | 0.00% |
| UTHR | -10.07% | $16.10B | +56.54% | 0.00% |
| INTC | -9.69% | $104.37B | -44.55% | 1.55% |
| ERJ | -9.69% | $6.92B | +134.10% | 0.00% |
| SLE | -9.52% | $8.82M | -63.18% | 0.00% |
| OXBR | -9.47% | $19.05M | +178.18% | 0.00% |
| PFG | -9.43% | $19.25B | +16.58% | 3.30% |
| LHX | -9.23% | $46.20B | +29.18% | 1.91% |
| MFG | -9.22% | $63.12B | +43.52% | 1.44% |
| BPT | -9.16% | $24.61M | -66.18% | 0.00% |
ETF's related to LUMO
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBJ | 21.52% | $109.21M | 0.62% |
| DIAL | 17.59% | $368.52M | 0.28% |
| AGGH | 16.89% | $253.02M | 0.33% |
| UDN | 16.75% | $56.29M | 0.78% |
| EMHC | 16.68% | $284.53M | 0.23% |
| VDC | 16.55% | $7.09B | 0.1% |
| TLTW | 16.53% | $1.09B | 0.35% |
| EYLD | 16.18% | $469.47M | 0.63% |
| PCY | 15.67% | $1.33B | 0.5% |
| FSTA | 15.48% | $1.20B | 0.084% |
| JPMB | 15.32% | $585.28M | 0.39% |
| PYLD | 15.18% | $2.25B | 0.55% |
| EAGG | 15.17% | $3.68B | 0.1% |
| SMMU | 15.17% | $624.12M | 0.35% |
| TLH | 15.16% | $7.01B | 0.15% |
| CEMB | 15.15% | $435.28M | 0.5% |
| VGLT | 15.06% | $12.70B | 0.04% |
| UITB | 15.02% | $2.36B | 0.38% |
| BBAG | 15.01% | $1.66B | 0.03% |
| VWOB | 14.92% | $5.40B | 0.2% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| COPX | -0.01% | $2.40B | 0.65% |
| FLTR | -0.01% | $1.79B | 0.14% |
| DBC | 0.07% | $1.39B | 0.87% |
| PXJ | -0.10% | $42.76M | 0.66% |
| FLOT | -0.13% | $7.31B | 0.15% |
| AGZD | 0.19% | $142.76M | 0.23% |
| FFOG | -0.20% | $118.40M | 0.55% |
| MLPX | 0.23% | $2.21B | 0.45% |
| FXU | 0.26% | $341.08M | 0.64% |
| IEZ | -0.39% | $153.88M | 0.4% |
| KLIP | 0.45% | $125.85M | 0.93% |
| PSI | -0.48% | $711.93M | 0.56% |
| PDBC | 0.58% | $4.40B | 0.59% |
| TPYP | 0.68% | $674.21M | 0.4% |
| TPMN | -0.73% | $40.60M | 0.65% |
| CGMU | 0.74% | $2.53B | 0.27% |
| XES | -0.76% | $208.58M | 0.35% |
| RPG | 0.79% | $1.52B | 0.35% |
| JPXN | -0.83% | $181.98M | 0.48% |
| DFNM | 0.84% | $1.40B | 0.17% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| UUP | -15.13% | $309.25M | 0.77% |
| USDU | -14.96% | $201.97M | 0.5% |
| DUSB | -9.91% | $797.63M | 0.15% |
| BTAL | -9.16% | $388.04M | 1.43% |
| EQLS | -8.57% | $76.08M | 1% |
| HEWJ | -8.23% | $347.32M | 0.5% |
| HEGD | -8.12% | $307.64M | 0.88% |
| DXJ | -7.16% | $3.71B | 0.48% |
| DBA | -6.99% | $755.88M | 0.93% |
| DBJP | -6.86% | $399.93M | 0.45% |
| FLJH | -6.66% | $74.69M | 0.09% |
| QQA | -6.26% | $135.01M | 0% |
| TBLL | -6.18% | $1.92B | 0.08% |
| BSJO | -5.78% | $467.93M | 0.43% |
| PSFF | -5.77% | $384.93M | 0.88% |
| EWJV | -5.73% | $258.12M | 0.15% |
| USCI | -5.69% | $185.47M | 1.07% |
| FMF | -5.68% | $244.61M | 0.95% |
| JBBB | -5.67% | $1.26B | 0.49% |
| SOXX | -5.67% | $13.20B | 0.35% |
News
Yahoo
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowt
Yahoo
Major U.S. stock indexes recently experienced mixed performance, with the Dow Jones and S&P 500 on track to end their six-week winning streaks amid a backdrop of critical economic data and earnings reports. In such a fluctuating market, identifying stocks that offer potential growth opportunities is key, especially when considering investments in smaller or newer companies often categorized as penny stocks. Despite being an outdated term, penny stocks still represent intriguing possibilities...
Yahoo
Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHDAUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the “Merger Agreement”) whereby Double Point Ventures
Yahoo
Lumos Pharma Inc (LUMO) reports progress in pivotal trials and strategic exploration, while managing financial resources effectively.
Yahoo
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Tri
Yahoo
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 i
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.